Buchumschlag

Digital healthcare solutions to better achieve the weight loss outcomes expected by payors and patients

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Louis Talay, Omar Alvi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Diabetes, Obesity and Metabolism
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Effectiveness and care continuity in an app‐based, glucagon‐like peptide‐1 receptor agonist‐supported weight‐loss service for women with overweight and obesity in the UK : A real‐world retrospective cohort analysis
von: Louis Talay, et al.
Veröffentlicht: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
von: Iskandar Idris, et al.
Veröffentlicht: (2025)

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
von: Malene Svoldgaard Sørensen, et al.
Veröffentlicht: (2025)

Impact of weight loss on obesity‐related complications and direct healthcare costs in Japan: A modelling study
von: Ataru Igarashi, et al.
Veröffentlicht: (2025)

Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
von: Francesco Cosentino, et al.
Veröffentlicht: (2024)

Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes
von: Anukriti Sharma, et al.
Veröffentlicht: (2024)

The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
von: Kim Henriksen, et al.
Veröffentlicht: (2025)

Incretin mimetics for weight loss forgive nonadherence
von: Anıl Cengiz, et al.
Veröffentlicht: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
von: Hans Johnson, et al.
Veröffentlicht: (2025)

Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States
von: Reema Mody, et al.
Veröffentlicht: (2025)

Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
von: Filipe A. Moura, et al.
Veröffentlicht: (2024)

Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
von: Juan Wang, et al.
Veröffentlicht: (2025)

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
von: Jason M. Samuels, et al.
Veröffentlicht: (2025)

Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study
von: Shambo S. Samajdar, et al.
Veröffentlicht: (2025)

Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
von: Danna M. Breen, et al.
Veröffentlicht: (2025)

A predictive model for medium‐term weight loss response in people with type 2 diabetes engaging in behavioural weight management interventions
von: Lulwa Al‐Abdullah, et al.
Veröffentlicht: (2024)

The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
von: Phil McEwan, et al.
Veröffentlicht: (2025)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
von: Zbigniew Siudak, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
von: Robert L. Dubin, et al.
Veröffentlicht: (2024)

Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta‐analysis
von: Ya‐Jun Xiao, et al.
Veröffentlicht: (2025)

A novel structured, volume‐based, weight‐loss and health programme combined with respiratory muscle training helps reduce weight and cardiovascular risk in people with obesity
von: Nina Bausek, et al.
Veröffentlicht: (2024)

A novel, centrally acting mammalian aminosterol, ENT ‐03, induces weight loss in obese and lean rodents
von: Denise Barbut, et al.
Veröffentlicht: (2024)

Histological efficacy of anti‐diabetic agents in MASH and the mediating role of weight loss: A network meta‐analysis
von: Mainak Banerjee, et al.
Veröffentlicht: (2025)

Actual weight loss trajectories after bariatric surgery compared with the SOPHIA prediction tool: An observational comparison study
von: Adhithya Sankar, et al.
Veröffentlicht: (2025)

Intermittent fasting for weight management and metabolic health: An updated comprehensive umbrella review of health outcomes
von: Zixin Hua, et al.
Veröffentlicht: (2024)

Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐ O trial
von: Hertzel C. Gerstein, et al.
Veröffentlicht: (2024)

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies
von: Reimar W. Thomsen, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
von: Amanda R. Purcell, et al.
Veröffentlicht: (2025)

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg
von: Susanne Kuckuck, et al.
Veröffentlicht: (2026)

An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
von: Matthias Blüher
Veröffentlicht: (2025)

A meta‐analysis of adverse offspring health outcomes in patients with gestational diabetes mellitus
von: Jiewen Guan, et al.
Veröffentlicht: (2025)

Changes in thyroid hormones predict weight regain in patients with obesity who undergo metabolic surgery
von: Yi Tang, et al.
Veröffentlicht: (2024)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
von: Erik Stenberg, et al.
Veröffentlicht: (2024)

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR / GLP ‐ 1R agonist survodutide in mice
von: Fen Long, et al.
Veröffentlicht: (2025)

Frequency and sequence of proteinuria positivity and clinical outcomes in patients with diabetes: A nationwide cohort study
von: Junseok Jeon, et al.
Veröffentlicht: (2025)

The association between glycaemic control, normal weight and long‐term macrovascular outcomes in people with type 2 diabetes in China: A retrospective study
von: Feng Sun, et al.
Veröffentlicht: (2025)

Comment to ‘Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—“ eCGM ”’
von: Ohad Cohen, et al.
Veröffentlicht: (2025)

Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes
von: Giovanni Antonio Silverii
Veröffentlicht: (2024)

Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—‘ eCGM ’ compliance status
von: Chantal Mathieu, et al.
Veröffentlicht: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
von: Matthew J. Armstrong, et al.
Veröffentlicht: (2024)